BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//ACC//Meetings//EN BEGIN:VTIMEZONE TZID:Eastern Standard Time BEGIN:STANDARD DTSTART:16011101T020000 RRULE:FREQ=YEARLY;BYDAY=1SU;BYMONTH=11 TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:Eastern Standard Time END:STANDARD BEGIN:DAYLIGHT DTSTART:16010301T020000 RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=3 TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:Eastern Daylight Time END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:\n\n\nWebinar Overview\nIn this webinar\, Alison Bailey\, MD\, FACC\, and Melvin R. Echols\, MD\, FACC\, discuss the emerging science and explore what is next for worsening HF. Specifically\, they will review th e new data\, including the SUMMIT trial\, the STEP-HFpEF program\, new dat a on GLP1-Ras and other emerging science. This webinar is part of the Tran sform HF Care: New Horizons in Treatment initiative\, supported by Bayer A G. Visit the Managing HF Across the Spectrum online course and access addi tional educational activities on this topic here.\nKey Objectives/Learning Outcomes:\n\nEvaluate the epidemiology\, risk factors\, comorbidities and community aspects associated with HF to determine best practices for care .\nDistinguish pathophysiologic characteristics when evaluating and diagno sing HF\, including current classifications\, genotypes and phenotypes\, t o analyze best HF risk stratification\, prevention and management strategi es.\nIncorporate guideline-directed medical therapy (GDMT)\, newer therapi es and interprofessional team strategies into treatment care plans for the management of HF to improve care coordination\, communication and patient outcomes.\n\n\nWebinar Recording\n\n\n-->\n\nWebinar Participants\nAlison Bailey\, MD\, FACC\nMelvin R. Echols\, MD\, FACC\n\nCredit Information\nN o credit is being offered for this webinar.\n\n\n\n\n\n .videoWrapper {\n position: relative\;\n padding-bottom: 56.25%\; /* 16:9 */\n padding-t op: 25px\;\n height: 0\;\n }\n .videoWrapper iframe {\n position: abso lute\;\n top: 0\;\n left: 0\;\n width: 100%\;\n height: 100%\;\n }\n\ n DTEND;TZID=Eastern Standard Time:20251209T183000 DTSTAMP:20260429T051050Z DTSTART;TZID=Eastern Standard Time:20251209T181500 LOCATION:Online - Eastern Time (ET) SEQUENCE:0 SUMMARY:Ask the Experts: What is the Emerging Science For Worsening HF? UID:20b701ad-9f26-4e42-9e27-24fabf06ee3f@acc.org X-ALT-DESC;FMTTYPE=text/html:
\n
\n\n

Webinar Overvi ew

\n

In this webinar\, Alison Bailey \, MD\, FACC\, and Melvin R. Echols\, MD\, FACC\ , discuss the emerging science and explore what is next for worsening HF. Specifically\, they will review the new data\, including the SUMMIT trial\ , the STEP-HFpEF program\, new data on GLP1-Ras and other emerging science . This webinar is part of the Transform HF Care: New Horizons in T reatment initiative\, supported by Bayer AG. Visit the Managing HF Across the Spectrum online course and access additional ed ucational activities on this topic here.

\n

Key Objectives/Learning Outcomes:

\n
    \n
  1. Evaluate the epidemiology\, risk factors\, comorbidities and community as pects associated with HF to determine best practices for care.
    2. \n
  2. D istinguish pathophysiologic characteristics when evaluating and diagnosing HF\, including current classifications\, genotypes and phenotypes\, to an alyze best HF risk stratification\, prevention and management strategies.< /li>\n
  3. Incorporate guideline-directed medical therapy (GDMT)\, newer th erapies and interprofessional team strategies into treatment care plans fo r the management of HF to improve care coordination\, communication and pa tient outcomes.
    4. \n
\n\n